About Us

Redefining the future of autoimmune disease treatment

At COUR, we are driven by a profound commitment to empowering people living with autoimmune disease. Led by a team of industry veterans with a proven track record of success in developing and commercializing biopharmaceuticals, we are positioned to deliver the next generation of disease-modifying therapies to patients with unprecedented speed.

Leadership

Dannielle Appelhans
President and CEO
Brian C. Bock
Chief Financial Officer
Paul M. Peloso, MD
Chief Medical Officer
Sarah Longoria
Chief People Officer
Adam Elhofy, PhD
VP, Research
Robert Hodge
VP, Technical Development
Lori Jester
VP, Manufacturing and Supply Chain
Stan Russell
VP, Quality
Tony Mitchell
VP, Controller
Andrea Chen
Executive Director, Head of Program Management
Leo P. Kelly
Executive Director, Strategic Alliances
Anju Samy, RPh, PhD
Executive Director, Head of Regulatory Affairs

Board of directors

President and CEO
Lead Independent Director
Alpha Wave Global,
LP Managing Director
Roche Venture Fund
Senior Investment Director
Founder, Former President and CEO
Lumira Ventures
Managing Director
Former Chairman, President, and Chief Executive Officer, Horizon Therapeutics;
Senior Advisor, Amgen

Advisors

COUR’s scientific and medical advisors bring unique perspectives and expertise to drive the strategic direction and success for potentially life-changing technology.

Harvard Medical School
University of California, Davis
Northwestern University
University of Michigan
University of Miami
Yale University
University of Colorado
Scroll to Top